Evidence map›Paper›PMID 32140785›Full record

ArticleJournal of bone and mineral metabolism2020

Skeletal and mineral metabolic effects of risedronate in a rat model of high-turnover renal osteodystrophy.

Hiroaki Ishida, Hirotaka Komaba, Naoto Hamano, Hideyuki Yamato, Kaichiro Sawada, Takehiko Wada, Michio Nakamura, Masafumi Fukagawa

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of bone and mineral metabolism, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Diffuse skeletal [Asia Oceania journal of nuclear medicine & biology · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Roles of osteocytes in phosphate metabolism.Frontiers in endocrinology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Hiroaki IshidaDepartment of Transplant Surgery, Tokai University School of Medicine, Isehara, Japan.
Hirotaka KomabaDivision of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, 143 Shimo-Kasuya, Isehara, 259-1193, Japan. hkomaba@tokai-u.jp.
Naoto HamanoDivision of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, 143 Shimo-Kasuya, Isehara, 259-1193, Japan.
Hideyuki YamatoDivision of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, 143 Shimo-Kasuya, Isehara, 259-1193, Japan.
Kaichiro SawadaDivision of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, 143 Shimo-Kasuya, Isehara, 259-1193, Japan.
Takehiko WadaDivision of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, 143 Shimo-Kasuya, Isehara, 259-1193, Japan.
Michio NakamuraDepartment of Transplant Surgery, Tokai University School of Medicine, Isehara, Japan.
Masafumi FukagawaDivision of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, 143 Shimo-Kasuya, Isehara, 259-1193, Japan.
Tokai University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionHigh-turnover bone disease is a major consequence of SHPT and may explain the high risk for fracture in patients with advanced chronic kidney disease (CKD). Bisphosphonates suppress bone turnover and improve bone strength, but their effects have not been fully characterized in advanced CKD with severe SHPT. Bisphosphonates also increase 1,25-dihydroxyvitamin D levels in normal and uremic rats, but the underlying mechanism remains to be determined. MATERIALS AND

methodsWe investigated the skeletal and mineral metabolic effects of RIS, a pyridinyl bisphosphonate, in rats with severe SHPT induced by 5/6 nephrectomy plus a high phosphate diet.

resultsNephrectomized rats developed severe SHPT, along with hyperphosphatemia, low 1,25-dihydroxyvitamin D, and markedly increased FGF23. Moreover, these rats exhibited characteristic features of high-turnover renal osteodystrophy, including increased indices of trabecular bone turnover, decreased cortical bone thickness, inferior cortical biomechanical properties, and a prominent increase in peritrabecular fibrosis. RIS treatment increased bone volume and partially attenuated trabecular bone remodeling, cortical bone loss, and mechanical properties, whereas it produced a marked improvement in peritrabecular fibrosis along with a corresponding decrease in osteogenic gene markers. RIS treatment also suppressed the elevation of FGF23, which was associated with increased 1,25-dihydroxyvitamin D.

conclusionsIn a rat model of severe SHPT, treatment with RIS partially attenuated histological manifestations of high-turnover bone disease. RIS treatment also suppressed the elevation of FGF23, which may explain the increased 1,25-dihydroxyvitamin D production during the treatment.

Indexed as

Bone RemodelingAnimalsBiomechanical PhenomenaBlood Urea NitrogenBone and BonesCalciumChronic Kidney Disease-Mineral and Bone DisorderCreatinineDisease Models, AnimalFibroblast Growth Factor-23Gene Expression RegulationHumansMaleMineralsNephrectomyPeptide FragmentsCalciumCreatinineFGF23 protein, humanFibroblast Growth Factor-23MineralsPeptide FragmentsPhosphorusProcollagenprocollagen Type I N-terminal peptideRisedronic AcidBisphosphonateChronic kidney diseaseFibroblast growth factor 23Secondary hyperparathyroidismVitamin D

Identifiers

PMID32140785
OpenAlexW3010103494

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.